All News
Watch: Treatment of Pre-RA: Is Early Already Too Late?
Dr. Aurelie Najm reviews abstract OP0070 presented at the #EULAR2022 meeting. #MedEd
https://t.co/ep4lgtZYcT https://t.co/LTx1RMGdkv
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 OP0067:
Depression is a major risk factor (6X!) for mortality in RA. Study may show some bias in the methods, but critical findings for all rheumatologists to consider
@RheumNow
https://t.co/leeY9zAx4T
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022
Ultrasound may be used to evaluate patients with RA (POS1393) and SSc (POS1394)
👁️Look for B-lines and pleural irregularity
Will require training of MSKUS rheumatologists, but another potential application of US in clinical practice
@RheumNow @MymaAlbaydaMD @USSONAR_Rh https://t.co/qtnBviKA3w
Eric Dein ericdeinmd ( View Tweet)
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa
Links:
Dr. John Cush RheumNow ( View Tweet)
A Big Leap in Modulating Rheumatoid Disease
Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic.
https://t.co/QHK7c3Qhz6 https://t.co/jFR9wDCD8o
Links:
Dr. John Cush RheumNow ( View Tweet)
CTD associated ILD 🫁:
lncRNA ENST00000604692 detected in PBMCs is associated with CTD-ILD and can distinguish SSc-
ILD and RA-ILD vs. non ILD patients with AUC 0.79.
As many lncRNA, unknown if biomarker only or has a pathogenic role.
@RheumNow OP0114 #EULAR2022 https://t.co/sR4GmaMkXD
Aurelie Najm AurelieRheumo ( View Tweet)
Lung 🫁 cancer incidence and RA
44000+ RA (EIRA prospective cohort) and 216000+ matched Ctrls Swedish registries
📍56 per 100,000
📍HR 1.77 (adjusted for smoking 🚬)
📍Risk in RA + smoking 7x higher
📍Risk 2x in Sero+ vs. sero-
No data on ttmt
#EULAR2022 @RheumNow POS0061 https://t.co/c7eh3icW2c
Aurelie Najm AurelieRheumo ( View Tweet)
B-cell depletion w/ RTX ttmt is FcγR dependant & affected by FcγRs variants 🧬
FCGR3A-158V:
*encodes the allotype ⬆️ affinity for IgG1
*is associated w/ clinical and biological responses in RA and SLE.
A new way to stratify pts for anti-CD20 therapy?
@Yuz6Yusof #EULAR2022 OP0190 https://t.co/GPiaQXaF71
Aurelie Najm AurelieRheumo ( View Tweet)
Karpouzas et al. ORAL Surveillance analysis. MACE, VTE, infections higher in those with acute and cumulative disease activity as measured by CDAI. @RheumNow #EULAR2022 POS0519 https://t.co/CtlISf2rxr
Richard Conway RichardPAConway ( View Tweet)
Rojas-Gimenez et al After adjusting for age, smoking, ACPA. Male sex (OR 4.2) and longer time of having RA (OR 1.08) associated with ILD @RheumNow #EULAR2022 POS0619 https://t.co/kzG76Qwe52
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0134: Active RA increases risk of dementia
Olmsted County, MINN studying RA risk factors for dementia:
⭐️886 pts incident RA, mean age 65. 103 develop dementia
Risk factors: Age, rheum nodules, large jt swelling, depression/anxiety, HTN, CVD events
@Rheumnow https://t.co/bUFkzBovAy
Eric Dein ericdeinmd ( View Tweet)
All the domains of sexual sphere are deteriorated in RA and PsA.
This aspect is often overlooked and can have a significant impact on pts QoL. It may be time to assess this aspect more specifically using CSFQ-14 and propose dedicated interventions. #OP0139 @RheumNow #EULAR2022 https://t.co/l0zyBIZ1LI
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2022 OP0139
Has your pt asked about sexual fxn?
Sexual dysfxn (SD) (CSFQ-14 questionnaire) and joint disease
188 AI pts, 89 controls
Nearly 50% of RA pts had SD, 30% in PsA. Only 6% in control group!
High depression in group, but not found as rf
@RheumNow https://t.co/WvBw3cnFKC
Eric Dein ericdeinmd ( View Tweet)
Patient with 12 weeks inflamm-sounding arthralgias and functional impairment, high titre RF/CCP, osteitis on MRI, no clinical synovitis on exam.
Do you suggest to patient to treat with methotrexate?
#EULAR2022 @RheumNow
David Liew drdavidliew ( View Tweet)
🚨 Study on MTX and male fertility
Analysis of semen parameters in
🙋🏼♂️HC
🙋🏼♂️RA, PsA and PsO MTX naive
🙋🏼♂️Post MTX
Reassuring data as NO significant effect of MTX was observed on several semen parameters.
#EULAR2022 @RheumNow
OP0131 https://t.co/Fq32lzAMAx
Aurelie Najm AurelieRheumo ( View Tweet)
Dementia in RA associated w/
⚡️Large joint swelling HR 2
⚡️Any CVD HR 2.25
⚡️Anxiety HR 1.86
⚡️Depression HR 2.63
at any time during disease course in retrospective cohort 800+ pts
#EULAR2022 @RheumNow OP0134 @MyasoedovaElena https://t.co/MLweRMEZXE
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2022 OP0135:
German RABBIT 🐇 Registry:
⭐️ Observational, 46% Tofa, 54% Bari
No increased rate of CVD in JAK vs TNF inhibitor
🚨Unlike the ORAL Surveillance
@RheumNow https://t.co/O4IXg22Ybc
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 OP0136:
PROTECT-RA Cohort - 150 pts established RA
Cholesterol loading capacity (CLC) on macrophages
⭐️High CLC correlates with CV events
⭐️bDMARD use affects CLC
@RheumNow https://t.co/9ngaH9yUI7
Eric Dein ericdeinmd ( View Tweet)
RABBIT registry and MACE in RA
No difference between
*JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients.
🧨 different than ORAL surveillance
but Observational and overall Low incidence (28 events).
#EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF
Aurelie Najm AurelieRheumo ( View Tweet)
The CONSUL study @ProftDr showed there was no significant difference in Celecoxib(CEL)+Golimumab (GOL) vs GOL alone. The mSASSS change was 1.1 vs 1.7, p=0.79 between the 2 groups. The combination may be clinically relevant in high-risk progressors #EULAR2022 @RheumNow OP0018 https://t.co/AUOL7IDx9L
Dr. Antoni Chan synovialjoints ( View Tweet)
